Tomoko Akaike

9PUBLICATIONS
34CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyPredictive and prognostic markersCancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Sep 19, 2025
Real-world outcomes of patients receiving salvage therapies for immune checkpoint inhibitor-resistant Merkel cell carcinoma: a rationale for future clinical trials.

Peter Y Ch'en, Yuzheng Zhang, Daniel S Hippe

|Aug 11, 2025
Risk of disease progression after discontinuing immunotherapy in 105 patients with Merkel cell carcinoma who responded to PD-1 pathway blockade.

Lisa Tachiki, Yasman Moshiri, Daniel S Hippe

|Mar 18, 2025
Immunotherapy response in immunosuppressed patients with Merkel cell carcinoma: analysis of 183 patients.

Emily Gong, Lauren Zawacki, Xinyi Fan

|Jul 25, 2024
Merkel cell carcinoma refractory to anti-PD(L)1: utility of adding ipilimumab for salvage therapy.

Tomoko Akaike, Austin J Jabbour, Peter H Goff

|Jul 25, 2024
Circulating Tumor DNA Assay Detects Merkel Cell Carcinoma Recurrence, Disease Progression, and Minimal Residual Disease: Surveillance and Prognostic Implications.

Tomoko Akaike, Manisha Thakuria, Ann W Silk

|Dec 11, 2022
Management and Prognosis of Cardiac Metastatic Merkel Cell Carcinoma: A Case-Control Study and Literature Review.

Tomoko Akaike, Kelsey Cahill, Gensuke Akaike

Pageof 2

Frequent Collaborators

9 joint publications

Paul T Nghiem

6 joint publications

Shailender Bhatia

5 joint publications

Song Youn Park

4 joint publications

Daniel S Hippe